Hodgkin Lymphoma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

56 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hodgkin Lymphoma
2020-004780-71: A study using a hormone drug during chemotherapy for fertility protection of young women and teenagers with cancer - ProFertil En studie med ett hormonpreparat som utvärderar effekten av fertilitet hos unga kvinnor och tonåringar med cancer - ProFertil

Not yet recruiting
3
500
Europe
Pamorelin, Powder and solvent for prolonged-release suspension for injection, Pamorelin
Karolinska University Hospital, Karolinska University Hospital
Breast CancerAcute LeukemiaLymphomas (Hodgkin and non-Hodgkin)Sarcomas (Osteo, Soft tissue and Ewing) Bröstcancer, Akut Leukemi, Lymfom (Hodgkin och non-Hodgkin), Sarkom (Ben, Mjukvävnad och Ewing), Breast CancerBlood CancerCancer in lymphnodesCancer in bones Bröstcancer, Blodcancer, Cancer i lymfkörtlar, Cancer i skelett, Diseases [C] - Cancer [C04]
 
 
2010-022844-19: Randomized phase III study of a treatment driven by early PET response compared to a treatment not monitored by early PET in patients with Ann Arbor Stage III-IV or high risk IIB Hodgkin lymphoma

Ongoing
3
810
Europe
Bleomycin, Prednisone, Vincristine, Doxorubicin, Cyclophosphamide, Dacarbazine, Etoposide, Procarbazine, Vinblastine, Powder for solution for injection, Tablet, Solution for injection, Powder for solution for infusion, Solution for infusion, Capsule*
CHU de Dijon
Hodgkin Lymphoma not previously treated
 
 
NCT00379041: Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Active, not recruiting
3
1158
NA
bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
10/98
 
NCT00002462: RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease

Active, not recruiting
3
615
Europe, RoW
bleomycin sulfate, doxorubicin hydrochloride, mechlorethamine hydrochloride, prednisone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma
05/00
 
NCT00005584: Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma

Active, not recruiting
3
1649
Europe
bleomycin sulfate, ABVD regimen, BEACOPP regimen, epirubicin hydrochloride, prednisone, vinblastine sulfate, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, UNICANCER
Lymphoma
05/04
 
2009-017279-77: Randomized Phase III study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non hodgkin's lymphoma CD 20+ Phase III randomisée multicentrique évaluant la non infériorité d’un traitement adapté à la réponse précoce au morphoTEP par rapport à un traitement standard pour les patients de 18 à 80 ans atteints d’un lymphome malin non hodgkinien B diffus à grandes cellules CD 20 + de faible risque (IPI aa=0)

Ongoing
3
650
Europe
rituximab, Prednisone, Doxorubicine, Cyclophosphamide, Vincristine, G-CSF, Concentrate for solution for infusion, Tablet, Solution for injection, Powder for injection, Unknown (not supplied)
LYSARC, INCa
Patient with Diffuse Large B cells with IPI=0 not previously treated, Patient with Diffuse Large B cells with IPI=0 not previously treated, Diseases [C] - Cancer [C04]
 
 
NCT00433433 / 2005-002765-37: Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma

Active, not recruiting
3
1952
Europe
ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual), Involved-Note Radiation Therapy, FDG-PET scan, F-18 fluorodeoxyglucose positron emission tomography scan
European Organisation for Research and Treatment of Cancer - EORTC, Lymphoma Study Association, Fondazione Italiana Linfomi ONLUS
Lymphoma
12/11
 
2009-010700-28: GRANITE-1 - Transmission of specific immune cells from healthy donors for cancer patients with fever, who lack these cells

Ongoing
3
200
Europe
Granulocyte-Transfusion, Granocyte-13, Neupogen 30, Neupogen 48, Granocyte 34, no product code available, Infusion, Powder and solvent for solution for injection, Solution for injection, GRANOCYTE 13, NEUPOGEN 30, NEUPOGEN 48, GRANOCYTE 34
University of Cologne, Deutsche Forschungsgesellschaft (DFG)
Febrile neutropenia due to chemotherapy for the following diseases:C92.0- - Acute myeloid leukemiaC91.0- - Acute lymphoblastic leukemiaC92.1- - Chronic myeloid leukemiaC91.1- - Chronic lymphoblastical leukemiaD46.9 - Myelodysplastic syndromeD47.1 - Chronic myeloproliferative diseaseC82.- - Follicular/nodular NHLD83.- - Diffuse Non-Hodgkin's Lymphoma (NHL)C84.4 - Peripheral T-Cell NHLC90.0- - Multiple myelomaC81.9 - Hodgkin's lymphoma (HL), Patients with cancer of the blood or the immunesystem who have a weak immunesystem due to chemotherapy,who develope fever during the time of a weak immunesystem can take part in this study., Diseases [C] - Cancer [C04]
 
 
ACTRN12610000927022: A randomised Phase III Trial to assess response adapted therapy using 2-[F-18]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) imaging in patients with newly diagnosed, advanced Hodgkin Lymphoma

Completed
3
1200
 
University College, National Health and Medical Research Council
Hodgkin Lymphoma
 
 
RAPID, NCT00943423: PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

Active, not recruiting
3
602
Europe
Involved Field Radiotherapy, No further treatment
University College, London, The Christie NHS Foundation Trust
Lymphoma
07/14
12/28
2007-005831-27: Use of rHuEpo before autologous hematopoietic stem cell transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer to reduce transfusional requirement after myeloablative conditioning. A monocentric, phase III, open study.

Ongoing
3
90
Europe
EPREX, EPREX
AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA\' GRANDA (A.O. DI RILIEVO NAZIONALE)
autologous hematopoietic stem cells transplantation in patients affected by multiple myeloma, non Hodgkin disease and breast cancer
 
 
2007-000230-39: Protective effect of gonadoliberin analogues on endocrine and reproduction ovarian function during antitumour treatment in young girls and women in fertile period: Project of pharmacological gonadal protection and protection of reproduction functions.

Ongoing
3
40
Europe
Diphereline S.R. 3 MG INJ, DIPHERELINE S.R. 3mg, DIPHERELINE S.R. 3mg
Endocrine Society of Czech Republic
The patient with diagnosis: Hodgkin disease and leukaemia. Patients starting at adolescence (B3 - B4 for breast development accordig Tanner criteria) till 34 years be included.
 
 
2007-003187-22: HD18 for advanced stages HD18 für fortgeschrittene Stadien

 
3
1600
Europe
Bleomycin, Etoposide, Doxorubicine, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Bleomycin, Etoposid, Doxorubicin, Endoxan, Oncovin, Procarbazine, Prednisone, Bleomycin, Etoposid, Doxorubicin, Endoxan, Oncovin, Procarbazine, Prednisone
University of Cologne, VU University Medical Center, , Deutsche Krebshilfe
Hodgkin´s lymphomaadvanced stage
 
 
2008-002684-14: Early salvage with high dose chemotherapy and stem cell transplantation in advanced stage Hodgkin’s lymphoma patients with positive positron emission tomography after two courses of ABVD (PET-2 positive) and comparison of radiotherapy versus no radiotherapy in PET-2 negative patients.

Ongoing
3
300
Europe
DOXORUBICINA BAXTER*EV 20FL50M, BLEOMICINA NIPPON K.*1F 15MG, VINBLASTINA BAX*INFUS 1FL 10MG, DETICENE*INFUS 100MG/10ML FL+F, DOXORUBICINA BAXTER*EV 20FL50M, BLEOMICINA NIPPON K.*1F 15MG, VINBLASTINA BAX*INFUS 1FL 10MG, DETICENE*INFUS 100MG/10ML FL+F
IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
HODGKIN LYMPHOMA
 
 
2007-004474-24: HD16 für frühe StadienTherapieoptimierungsstudie in der Primärtherapie des frühen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET

Ongoing
3
1150
Europe
Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, L01DB01, L01DC01, L01CA01, L01AX04, Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
University of Cologne, VU University Medical Center, , Deutsche Krebshilfe
Hodgkin´s Lymphoma early stage
 
 
RATHL, NCT00678327 / 2007-006064-30: Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Completed
3
1202
Europe
bleomycin sulfate, filgrastim, pegfilgrastim, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, prednisolone, procarbazine hydrochloride, vinblastine sulfate, vincristine sulfate
University College, London, Cancer Research UK, Cancer Research UK & UCL Cancer Trials Centre
Lymphoma
01/16
05/24
2011-000088-28: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial

Ongoing
3
300
Europe
Sirolimus, Mycophenolatmofetil, Cyclosporine, EU/1/01/171/007, EU/1/01/171/001, EU/1/96/005/001, EU/1/96/005/004, EU/1/96/005/005, Coated tablet, Oral liquid, Capsule, Tablet, Powder for concentrate for solution for infusion, Capsule, soft, Oral suspension, Concentrate and solvent for concentrate for solution for infusion, Rapamune, CellCept, Sandimmun
Fred Hutchinson Cancer Research Center
Graft versus host disease, Graft versus host disease is a process where donor cells may react against cells of your body causing inflammation that can involve the skin, liver and gastrointestinal system., Not possible to specify
 
 
ECHELON-1 , NCT01712490 / 2011-005450-60: A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Checkmark Six year data from ECHELON-1 study for advanced classical Hodgkin lymphoma
Jul 2022 - Jul 2022: Six year data from ECHELON-1 study for advanced classical Hodgkin lymphoma
Checkmark Full data from ECHELON-1 trial in Hodgkin lymphoma at ASCO 2022
May 2022 - May 2022: Full data from ECHELON-1 trial in Hodgkin lymphoma at ASCO 2022
Checkmark Five year data from ECHELON-1 study for advanced classical Hodgkin lymphoma at ASH 2020
More
Active, not recruiting
3
1334
Europe, Canada, Japan, US, RoW
brentuximab vedotin, ADCETRIS®, SGN-35, doxorubicin, Adriamycin, bleomycin, vinblastine, dacarbazine, DTIC
Takeda, Seagen Inc.
Hodgkin Lymphoma
04/17
01/26
HD16, NCT00736320: for Early Stage Hodgkin Lymphoma

Active, not recruiting
3
1150
Europe
ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine), 20 Gy IFRT (Involved Field Radiotherapy)
University of Cologne
Hodgkin Lymphoma
09/18
12/21
ACTRN12618000069257: European Network-Paediatric Hodgkin Lymphoma Study Group: Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Active, not recruiting
3
160
 
Justus Liebig University of Giessen, My Room - Children's Cancer Charity
Classical Hodgkin Lymphoma
 
 
2021-001385-38: RANDOMIZED STUDY TO PROTECT FROM RADIATION IATROGENIC HYPOTHYROIDISM PATIENTS WITH MEDULLOBLASTOMA (ANY AGE, STAGE AND ANY BIOLOGICAL RISK) AND PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA NEEDING RADIATION THERAPY ON THYROID SITE Studio randomizzato per proteggere da ipotiroidismo iatrogeno dovuto ad irradiazione pazienti con medulloblastoma (qualsiasi età, stadio e qualsiasi rischio biologico) e pazienti pediatrici con linfoma di Hodgkin e linfoma non-Hodgkin che necessitano di radioterapia includente la sede tiroidea

Ongoing
3
51
Europe
Levotiroxina, [Levotiroxina], Tablet
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
medulloblastoma, Hodgkin and non-Hodgkin lymphomas medulloblastoma, linfomi di Hodgkin e linfomi non-Hodgkin, medulloblastoma, Hodgkin and non-Hodgkin lymphomas medulloblastoma, linfomi di Hodgkin e linfomi non-Hodgkin, Diseases [C] - Cancer [C04]
 
 
FIL-Rouge, NCT03159897 / 2016-002509-21: FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Active, not recruiting
3
500
Europe
Doxorubicin, Bleomycin, Vinblastine, Dacarbazine
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/21
09/24
AHOD1331, NCT02166463: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Checkmark Approved for 1L high-risk Hodgkin lymphoma in children and young adults based on AHOD1331 trial
Nov 2022 - Nov 2022: Approved for 1L high-risk Hodgkin lymphoma in children and young adults based on AHOD1331 trial
Checkmark Submitted for 1L high-risk Hodgkin lymphoma in children [Based on AHOD1331 trial]
Jul 2022 - Jul 2022: Submitted for 1L high-risk Hodgkin lymphoma in children [Based on AHOD1331 trial]
Checkmark Data from the AHOD1331 trial in children with newly diagnosed high-risk Hodgkin lymphoma at ASCO 2022
More
Active, not recruiting
3
600
Canada, US
Bleomycin Sulfate, Blanoxan, BleMomycine, Blenoxane, Bleo-cell, Bleo-S, Bleocin, Bleolem, Bleomycin Sulfas, Bleomycin Sulphate, Bleomycini Sulfas, Blexane, Oil Bleo, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Laboratory Biomarker Analysis, Methylprednisolone, Adlone, Caberdelta M, DepMedalone, Depo Moderin, Depo-Nisolone, Duralone, Emmetipi, Esametone, Firmacort, Medlone 21, Medrate, Medrol, Medrol Veriderm, Medrone, Mega-Star, Meprolone, Methylprednisolonum, Metilbetasone Solubile, Metrocort, Metypresol, Metysolon, Predni-M-Tablinen, Prednilen, Radilem, Sieropresol, Solpredone, Summicort, Urbason, Veriderm Medrol, Wyacort, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
12/21
09/24
ACTRN12617000087358: Treatment optimisation trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD.

Active, not recruiting
3
1585
 
University of Cologne, Millennium Pharmaceuticals
Advanced stage Hodgkin lymphoma
 
 
2022-000371-39: MK-4280A versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, relapsed/refractory Classical Hodgkin Lymphoma

Ongoing
3
360
Europe
MK4280A (Favezelimab + Pembrolizumab), MK4280A, Solution for infusion, Bendamustine, Gemcitabine
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma, Relapsed or Refractory Classical Hodgkin Lymphoma, Diseases [C] - Cancer [C04]
 
 
HD21, NCT02661503 / 2014-005130-55: for Advanced Stages

Active, not recruiting
3
1500
Europe
Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, Brentuximab Vedotin, Dacarbazine, Dexamethasone
University of Cologne
Classical Hodgkin Lymphoma
12/22
09/25
NCT03480360: Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression

Active, not recruiting
3
21
US
Cyclophosphamide, Fludarabine, Total Body Irradiation, Tacrolimus, cellcept, g-csf, Peripheral Blood Transplant
Dartmouth-Hitchcock Medical Center
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Myelodysplasia, Myeloproliferative Disorder, Myelofibrosis, Lymphoma, Lymphoma, Non-Hodgkin, Plasma Cell Disorder
03/23
09/25
MI-Immune, NCT03959241: TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)

Completed
3
431
US
Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate, HSCT, Tacrolimus, Prograf®, FK506, Methotrexate, MTX, Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Mycophenolate Mofetil/Post-Transplant Cyclophosphamide, Mycophenolate Mofetil, CellCept®, MMF, Cyclophosphamide, Cytoxan®
Medical College of Wisconsin, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia, Lymphoma
09/22
09/22
NCT04044222: A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy

Recruiting
3
240
RoW
Sintilimab, Carboplatin, Etoposide, Ifosfamide, Placebo
Innovent Biologics (Suzhou) Co. Ltd.
Classic Hodgkin's Lymphoma
07/23
12/24
NCT04342936: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
3
56
RoW
Camrelizumab, SHR-1210, Investigator's choice of Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Classical Hodgkin Lymphoma
08/23
12/23
NCT06170489: A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Recruiting
3
185
RoW
JS004 in combination with Toripalimab, Bendamustine or gemcitabine
Shanghai Junshi Bioscience Co., Ltd.
Hodgkin Lymphoma
05/25
09/27
HL-Russia-1, NCT04638790: First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia

Recruiting
3
300
RoW
Doxorubicin, ABVD, Bleomycin, Vinblastine, Dacarbazine, Etoposide, EACODD-14, Cyclophosphamide, Vincristine, Dexamethasone
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Hodgkin Lymphoma, Adult
12/26
12/26
SWOG S1826, NCT03907488: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Active, not recruiting
3
995
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
03/24
04/25
NCT06465446: A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting
3
202
NA
Tislelizumab, IMM01, Timdarpacept, Bendamustine, Gemcitabine
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Classic Hodgkin Lymphoma
06/26
07/29
ReSPECT, NCT04368559 / 2017-004981-85: Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
3
600
Europe, Canada, US, RoW
Rezafungin for Injection, Intravenous antifungal therapy, Posaconazole, Noxafil, Fluconazole, Generic Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Bactrim, Septra, Intravenous Placebo, Placebo Infusion, Oral Placebo, encapsulated cellulose
Mundipharma Research Limited
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
12/25
12/25
RATIONALE-314, NCT04486391: Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting
3
123
RoW
Tislelizumab, BGB-A317, Salvage Chemotherapy
BeiGene
Classical Hodgkin Lymphoma
09/24
03/25
OPTIMAL>60, NCT01478542 / 2010-019587-36: / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine

Checkmark ASH 2014
Nov 2014 - Nov 2014: ASH 2014
Checkmark P3 enrollment initiation in 1st line, adult NHL pts
Nov 2011 - Nov 2011: P3 enrollment initiation in 1st line, adult NHL pts
Completed
3
1152
Europe
Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab, optimised rituximab-schedule
Universität des Saarlandes, German High-Grade Non-Hodgkin's Lymphoma Study Group, Spectrum Pharmaceuticals, Inc
CD20+ Aggressive B-Cell Lymphoma
01/24
01/24
NCT04459416: Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

Active, not recruiting
3
300
US
Acupuncture, opioid, Assessments
Memorial Sloan Kettering Cancer Center, Patient-Centered Outcomes Research Institute, Hackensack Meridian Health
Multiple Myeloma, Hodgkin Disease, Non-Hodgkin Lymphoma
06/25
06/25
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/24
NCT05518318: GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)

Not yet recruiting
3
60
NA
GLS-010, GLS-010 therapy, Chemotherapy of Investigator's choice
Guangzhou Gloria Biosciences Co., Ltd.
Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/25
06/25
KEYNOTE-204, NCT02684292 / 2015-005053-12: Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/)

Checkmark From KEYNOTE-204 trial in r/r classical Hodgkin’s lymphoma
Feb 2022 - Feb 2022: From KEYNOTE-204 trial in r/r classical Hodgkin’s lymphoma
Checkmark Expanded label in Keytruda for treatment of patients with classical Hodgkin lymphoma (cHL) after prior therapies
Mar 2021 - Mar 2021: Expanded label in Keytruda for treatment of patients with classical Hodgkin lymphoma (cHL) after prior therapies
Checkmark Efficiancy & safety data from KEYNOTE-204 study compared to brentuximab vedotin for r/r chronic Hodgkin's lymphoma
More
Active, not recruiting
3
304
NA
pembrolizumab, MK-3475, KEYTRUDA®, brentuximab vedotin, ADCETRIS®
Merck Sharp & Dohme LLC
Hodgkin Lymphoma
07/25
07/25
NCT05244642: A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma

Recruiting
3
60
RoW
Penpulimab, AK105, Investigator's choice of Chemotherapy
Akeso, Beijing Cancer Hospital
Hodgkin Disease Lymphoma
12/25
03/26
NCT05466318: ChiCGB vs BEAM in High-risk or R/R Lymphomas

Recruiting
3
306
RoW
Chidamide, Cladribine, Gemcitabine, Busulfan, Carmustine, Etoposide, Cytarabine, Melphalan, Autologous hematopoietic stem cell transplant
Sichuan University
Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell
12/25
12/25
BELINDA, NCT03570892 / 2016-002966-29: Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

Checkmark From BELINDA trial for 2L DLBCL [Did not met primary end point]
Aug 2021 - Aug 2021: From BELINDA trial for 2L DLBCL [Did not met primary end point]
Active, not recruiting
3
331
Europe, Japan, US, RoW
Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma
05/21
02/26
EuroNet-PHL-C2, NCT02684708: Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Active, not recruiting
3
2200
Europe, RoW
cyclophosphamide, vincristine, prednisone, dacarbazine, CYC, VCR, PRED, DTIC, cyclo, vcr, pred, dacarb,etop and doxo, CYC, VCR, PRED, DTIC, ETO, DOXO
University of Giessen, Deutsche Krebshilfe e.V., Bonn (Germany), Euronet Worldwide
Classical Hodgkin Lymphoma
09/26
09/26
EPCORE DLBCL-2, NCT05578976 / 2021-000168-31: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Recruiting
3
900
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Cyclophosphamide, Rituximab, Vincristine, Doxorubicin, Prednisone
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
09/28
12/29
ARCHED, NCT05820841: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma

Recruiting
3
330
Europe
R-miniCHOP + Acalabrutinib, R-miniCHOP
Universität des Saarlandes, University of Leipzig, University Hospital Regensburg, Wuerzburg University Hospital, University Hospital of Gießen and Marburg, Saarland University Medical Center, AstraZeneca
Large B-cell Lymphoma, Diffuse Large B Cell Lymphoma
04/28
12/28
NCT05711628: A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Withdrawn
3
334
NA
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Bendamustine, SDX-105, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pembrolizumab, BCD-201, Keytruda, Lambrolizumab, MK-3475, Pembrolizumab Biosimilar BCD-201, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Transplant Conditioning, conditioning regimen, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine
National Cancer Institute (NCI)
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
06/28
06/28
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
AHOD2131, NCT05675410: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Recruiting
3
1875
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bleomycin Sulfate, Blanoxan, BleMomycine, Blenoxane, Bleo-cell, Bleo-S, Bleocin, Bleolem, Bleomycin Sulfas, Bleomycin Sulphate, Bleomycini Sulfas, Blexane, Oil Bleo, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Etoposide Phosphate, Etopophos, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Involved-site Radiation Therapy, ISRT, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Dacortin H, Decaprednil, Decortin H, Delta(1)Hydrocortisone, Delta- Cortef, Delta-Cortef, Delta-Diona, Delta-F, Delta-Phoricol, Delta1-dehydro-hydrocortisone, Deltacortril, Deltahydrocortisone, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Metacortandralone, Meti Derm, Meticortelone, Opredsone, Panafcortelone, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Predni-Helvacort, Prednicortelone, Prednisolonum, Prelone, Prenilone, Sterane, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Procarbazine Hydrochloride, Benzamide, N-(1-methylethyl)-4-[(2-methylhydrazino) methyl]-, monohydrochloride (9CI), Ibenzmethyzine hydrochloride, Matulane, MIH hydrochloride, Natulan, Natulanar, Natunalar, NCI C01810, NCI-C01810, NCIC01810, p-(N'-methylhydrazinomethyl)-N-isopropylbenzamide hydrochloride, p-Toluamide, N-isopropyl-.alpha.-(2-methylhydrazino)-, monohydrochloride (8CI), PCB, PCB Hydrochloride, PCZ, Ro 4 6467/1, Ro 4-6467/1, Questionnaire Administration, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
04/31
04/31
KEYFORM-008, NCT05508867 / 2022-000371-39: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Recruiting
3
360
Europe, Canada, US, RoW
favezelimab/pembrolizumab, MK-4820A, bendamustine, BENDEKA®, gemcitabine, GEMZAR®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Hodgkin Lymphoma
05/27
06/31
NCT00981760: Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Recruiting
2/3
20
US
Total Body Irradiation, TBI, Fludarabine, Recipient Leukocyte Infusion, RLI
Massachusetts General Hospital
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma
06/10
06/10
NCT04510610: Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Recruiting
2/3
100
RoW
Camrelizumab and Decitabine
Chinese PLA General Hospital
Hodgkin Lymphoma
01/22
01/25
NCT06563245: Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Not yet recruiting
2/3
96
NA
Brentuximab Vedotin for Injection, response-adapted radiation, Doxorubicin, Etoposide, Prednisone, Cyclophosphamide, Dacarbazine, Tislelizumab Injection, Bedamustine
Children's Cancer Group, China, Shanghai Children's Medical Center, Najing Children's Hospital, West China Second University Hospital, Qilu Hospital of Shandong University, Tianjin Medical University Cancer Institute and Hospital, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, Xiangya Hospital of Central South University, The First Affiliated Hospital of Zhengzhou University, Second Affiliated Hospital of Anhui Medical University, Children's Hospital of Hebei Province, Children's Hospital of Henan Province, Sun Yat-Sen Memorial Hospital Zhongshan University
Classical Hodgkin Lymphoma, Child, Adolescent, Young Adult, Metabolic Response, Survival, Treatment, Brentuximab Vedotin, PET Scan
11/29
11/39
NCT05595447: Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Recruiting
2/3
20
RoW
Brentuximab Vedotin 50 MG [Adcetris], Nivolumab, Pembrolizumab
Hospital Regional de Alta Especialidad del Bajio, Universidad de Guanajuato
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
10/25
10/25
NCT04799275: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Recruiting
2/3
422
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Oral Azacitidine, Azacitidine Oral, CC 486, CC-486, CC486, Onureg, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
03/26
03/26

Download Options